Clinical and Cognitive Sciences Research Group, Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Salford Royal Hospital, Salford, UK.
Neuropathol Appl Neurobiol. 2014 Oct;40(6):686-96. doi: 10.1111/nan.12092.
Pathological heterogeneity within patients with frontotemporal lobar degeneration (FTLD) in general precludes the accurate assignment of diagnostic subtype in life. The aim of this study was to assess the extent of microglial cell activation in FTLD in order to determine whether it might be possible to employ this as a diagnostic marker in vivo using PET ligand 11C-PK11195 in order to differentiate cases of FTLD according to histological subtype.
The distribution and extent of microglial cell activation was assessed semi-quantitatively in cortical grey and subcortical white matter of CD68 immunostained sections of frontal and temporal cortex from 78 pathologically confirmed cases of FTLD, 13 of Alzheimer's disease (AD) and 13 controls.
Significantly higher levels of microglial cell activation than controls occurred in all four regions in FTLD, and in three of the four regions in AD. Microglial activation was greater in frontal subcortical white matter in FTLD than AD, whereas it was higher in temporal cortical grey matter in AD than FTLD. Microglial cell activation was significantly higher in temporal subcortical white matter in FTLD-MAPT than in other genetic (GRN, C9ORF72) or non-genetic forms of FTLD.
The present study suggests that high levels of microglial cell involvement in temporal lobe (subcortical white matter) might serve as a marker of inherited FTLD associated with intronic mutations in MAPT, with a relatively intense signal in this region in PET studies using 11C-PK11195 as microglial cell marker could indicate the presence of MAPT mutation in vivo.
额颞叶变性(FTLD)患者的病理异质性通常使在生前准确确定诊断亚型变得不可能。本研究旨在评估 FTLD 中小胶质细胞激活的程度,以确定是否可以使用 PET 配体 11C-PK11195 将其作为体内诊断标志物,根据组织学亚型对 FTLD 病例进行区分。
通过 CD68 免疫染色的额叶和颞叶皮质组织切片,对 78 例经病理证实的 FTLD 病例、13 例阿尔茨海默病(AD)病例和 13 例对照的皮质灰质和皮质下白质中的小胶质细胞激活的分布和程度进行半定量评估。
与对照组相比,FTLD 患者的所有四个区域以及 AD 患者的三个区域中的小胶质细胞激活水平均显著升高。FTLD 患者的额皮质下白质中的小胶质细胞激活高于 AD 患者,而 AD 患者的颞皮质灰质中的小胶质细胞激活高于 FTLD 患者。FTLD-MAPT 中颞皮质下白质中的小胶质细胞激活显著高于其他遗传(GRN、C9ORF72)或非遗传形式的 FTLD。
本研究表明,颞叶(皮质下白质)中小胶质细胞的高参与水平可能是与 MAPT 内含子突变相关的遗传性 FTLD 的标志物,使用 11C-PK11195 作为小胶质细胞标志物的 PET 研究中,该区域的信号较强,可能表明体内存在 MAPT 突变。